The advent of nanotechnology has brought about revolutionary innovations in biological research techniques and medical practice. In recent years, various “smart” nanocarriers have been introduced to deliver therapeutic agents specifically to the tumor tissue in a controlled manner, thereby minimizing their side effects and reducing both dosage and dosage frequency. A large number of nanoparticles have demonstrated initial success in preclinical evaluation but modest therapeutic benefits in the clinical setting, partly due to insufficient delivery to the tumor site and penetration in tumor tissue. Therefore, a precise understanding of the relationships betweenthe physicochemical properties of nanoparticles and their interaction with the surrounding microenvironment in the body is extremely important for achieving higher concentrations and better functionality in tumor tissues. This knowledge would help to effectively combine multiple advantageous functions in one nanoparticle. The main focus of the discussion in this review, therefore, will relate to the main physicochemical properties of nanoparticles while interacting within the body and their tuning potential for increased performance.

Iron oxide nanoparticles have emerged as multifunctional compounds with prominent potential in cancer theranostics, particularly in photothermal therapy (PTT) and photodynamic therapy (PDT). Their unique electronic and crystal structures, such as the dispersion of Fe²⁺ and Fe³⁺ ions and d-orbital splitting, contribute to their magnetic and catalytic properties. In PTT, Fe₃O₄ nanoparticles exhibit moderate near-infrared (NIR) absorption and photothermal conversion efficiency, which can be enhanced through adjustments in particle size, surface modification, and combinations with other components. In PDT, Fe₃O₄ nanoparticles demonstrate intrinsic peroxidase-like catalytic activity, facilitating Fenton and photo-Fenton reactions that generate reactive oxygen species (ROS), including hydroxyl radicals (^•OH), thereby amplifying oxidative stress in cancer cells. These nanoparticles can also function as carriers for photosensitisers (PS), promoting targeted delivery and enhanced ROS generation. Multifunctional nanomaterials that integrate Fe₃O₄ with other therapeutic agents and targeting ligands have demonstrated synergistic antitumour effects through amplified photothermal, photodynamic, chemodynamic, and chemotherapeutic mechanisms. Despite certain drawbacks, such as relatively low NIR absorption and challenges in optimising delivery and light activation, ongoing improvements in Fe₃O₄-based nanoplatforms present significant potential for enhancing treatment outcomes and the precision of cancer therapy. This article systematically explores the synergistic role of Fe₃O₄ nanoparticles in PTT and PDT, encompassing their magnetic and catalytic characteristics. Additionally, it focuses on multifunctional hybrid nanoplatforms that combine Fe₃O₄ with targeting or imaging agents, highlighting their potential to enhance therapeutic precision.

SUMMARY: Pulmonary ionocytes are rare cells in submucosal gland (SMG)–containing airways thought to have specialized ion transport properties that regulate airway surface fluid and mucus composition. The origins of pulmonary ionocytes remain unclear, but their association with airway SMGs suggests they may arise from specialized progenitors in this compartment. We show that mouse glandular myoepithelial cells (GMECs) have a unique capacity to specify ionocytes enriched in the Cftr channel. The Lef1 transcription factor was both necessary and sufficient to promote GMEC specification of ionocytes in mouse trachea, 3D organoids, and/or air-liquid interface (ALI) cultures. Overexpression of Lef1 (Lef1 ^OE ) in GMECs produced ionocyte-enriched epithelia with enhanced Cftr-mediated chloride, bicarbonate, and fluid transport properties. Moreover, Foxi1 knockout in Lef1 ^OE GMECs prevented ionocyte formation while promoting specification of Cftr-expressing secretory cells. These findings provide a progenitor relationship for the anatomical association of ionocytes with SMGs and a transcriptional framework for coordinated specification of CFTR-expressing ionocytes and secretory cells. Highlights: • Glandular myoepithelial cells give rise to pulmonary ionocytes in submucosal glands and the surface airway epithelium of mice. • Disruption of Lef1 in SMG progenitors decreases ionocyte specification and reduces CFTR-mediated anion transport. • Overexpression of the Lef1 transcription factor in glandular progenitors promotes ionocyte frequency, CFTR-mediated fluid transport, and chloride and bicarbonate conductance. •Disruption of Foxi1 in SMG progenitors abolishes Lef1-dependent ionocyte specification and reduces CFTR-mediated anion transport.

Background: Airway submucosal gland progenitors (SMGPs) serve as reserve stem cells for epithelial regeneration, yet mechanisms governing their long-term maintenance remain poorly understood. Here, we identify Ncf1/Igfbp2 signaling as a regulator of mouse SMGP fitness and epithelial lineage specification. Methods: Mouse SMGPs with genetic disruption of Ncf1 or Igfbp2 were serially passaged to assess progenitor proliferation, organoid-forming capacity, epithelial marker expression, DNA damage, DNA repair responses, and telomere length. Differentiated epithelia were evaluated for Cftr-mediated anion transport and pulmonary ionocyte specification in vitro and in vivo. Results: Genetic disruption of Ncf1 or Igfbp2 preserved SMGP identity, enhanced proliferative and organoid-forming capacity, and reduced DNA damage accumulation through activation of DNA repair programs. Epithelia derived from Ncf1 ^−/− and Igfbp2 ^−/− SMGPs maintained higher Cftr-mediated anion transport at late passage and exhibited enhanced pulmonary ionocyte specification in vitro and in vivo. These effects occurred independently of telomere shortening, implicating altered stress responses and DNA damage handling rather than replicative limits. Conclusions: Together, our findings identify Ncf1/Igfbp2 signaling as a regulator of airway stem cell fitness and epithelial maturation, with implications for regenerative therapies in lung diseases such as cystic fibrosis.

Background: Understanding the relationships between the methylenetetrahydrofolate reductase (MTHFR) gene polymorphism, colorectal polyps, and CRC risk can aid in advancing personalized medicine approaches in CRC prevention. The aim of the current study is to identify the association of C677T polymorphism of the MTHFR gene with the risk of colorectal polyps in the Azerbaijani population. Methods: This study included 125 patients with colon polyps and 155 healthy individuals as a control group. DNA was extracted from venous blood samples obtained from patients and healthy individuals, and the results were analyzed through polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and agarose gel electrophoresis. Results: Wild-type, heterozygote, and homozygous mutant were revealed within 69 (55.2%), 49 (39.2%), and 7 (5.6%) patients and within 100 (64.5%), 45 (29%), and 10 (6.5%) healthy controls, respectively. However, no significant statistical associations were observed between CT and TT genotypes, dominant (CC vs. CT + TT) and recessive (CC + CT vs. TT) models, and the mutant T allele and disease risk. There were also no significant differences between patients and controls regarding age, sex, smoking and alcohol use. Conclusion: Our research did not reveal any significant association between the MTHFR C677T polymorphism and susceptibility to colorectal polyps in the Azerbaijan population.